A Multi-Center, Investigator-Masked, Randomized, Crossover, Equivalence Study of the Safety and Efficacy of Once Daily Brimonidine Tartrate 0.35% Ophthalmic Suspension Compared with Brimonidine Tartrate 0.1% Ophthalmic Solution (Alphagan® P 0.1%) Dosed Three Times Daily in Subjects with Open Angle Glaucoma, Chronic Angle Closure Glaucoma with Patent Iridotomy/Iridectomy, or Ocular Hypertension.
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2017
At a glance
- Drugs Brimonidine (Primary)
- Indications Glaucoma; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Sun Pharma Advanced Research Company
- 19 Jul 2017 Status changed from recruiting to completed.
- 05 Apr 2017 New trial record